by Shroufi A, Govender NP, Meintjes G, Black J, Nel J, Moosa M-YS, Menezes C, Dawood H, Wilson D, Trivino Duran L, Ajose O, Murphy RA, Harrison T, Loyse A, Ruffell C, Van Cutsem G . International Journal of Infectious Diseases 2020, doi: 10.1016/j.ijid.2020.02.057
Summary: Flucytosine is recommended by the World Health Organization as part of the treatment for cryptococcal meningitis, but market failure has meant that flucytosine is not accessible in African treatment programmes. The recently established South African flucytosine clinical access programme is an attempt to address this market failure by making the medicine freely available to tertiary hospitals in South Africa. The authors describe why this programme was needed, its catalytic potential, and what is still required to ensure widespread access to flucytosine, and advocate that access programmes for medicines be utilized more widely as part of the solution to addressing market failure.
This article is a journal pre-proof.
Forbes [17 February 2020]
“National Sleeping Sickness Day: Government determined to eliminate trypanosomiasis by 2030”
“The Democratic Republic of the Congo starts using a medicine against sleeping sickness”
“RD. of Congo began using an innovative medicine against sleeping sickness”
“The DRC begins using an innovative medicine against sleeping sickness”
“DRC: Launch in Kinshasa of ‘fexinidazole’, a new oral treatment for sleeping sickness”
“Fight against sleeping sickness: The DRC registers therapeutic advances following a new treatment (PNLTHA Director)”